Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test
(NASDAQ:GH) PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield™ blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Sensitivity for detection of stage I CRC was 62%. “We are pleased with the performanc
Related Questions
How will the updated clinical results for Shield's V2 algorithm affect Guardant Health's revenue forecasts and valuation?
What are the implications of the 84% sensitivity and 90% specificity compared to existing colorectal cancer screening methods and competitors in the market?
What is the expected timeline for FDA approval and commercial rollout of the V2 algorithm, and how might that influence short‑term stock volatility?